Share：
Share this content in WeChat
X
[Chinese][PDF]693101
• Review •
Progress of breast imaging in Radiological Society of North America 2012
ZHAO Li-yun  ZHOU Chun-wu  LI Jing 

DOI:10.3969/j.issn.1674-8034.2013.02.016.


[Abstract] About 339 abstracts referring to breast imaging were included in Radiological Society of North America 2012. In terms of imaging technique, articles related to MRI account for about 30%, followed by ultrasonography, digital mammography, digital breast tomosynthesis and molecular imaging. Research contents focus on application of new technology, screening, response evaluation of neoadjuvant chemotherapy and localization for breast.
[Keywords] Breast diseases；Diagnostic imaging

ZHAO Li-yun Department of Diagnostic Radiology, Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China

ZHOU Chun-wu* Department of Diagnostic Radiology, Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China

LI Jing Department of Diagnostic Radiology, Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China

*Correspondence to: Zhou CW, E-mail: cjr.zhouchunwu@vip.163.com

Conflicts of interest   None.

Received  2012-12-28
Accepted  2013-01-20
DOI: 10.3969/j.issn.1674-8034.2013.02.016
DOI:10.3969/j.issn.1674-8034.2013.02.016.

[1]
Brem RF, Schoonjans JM, Kieper DA, et al. High-resolution scintimammography: a pilot study. J Nucl Med, 2002, 43(7): 909-915.
[2]
Coffey CM, Brem RF, Lieberman JH, et al. Breast-specific gamma imaging (BSGI) for the detection of mammographically occult breast cancer in high-risk women. Chicago: RSNA, 2012: DOI: .
[3]
Velez MB, Kieper DA, Chang TS, et al. The role of molecular breast imaging in patient management in a community breast center. Chicago: RSNA, 2012: DOI: .
[4]
Rapelyea JA, Vasnani RJ, Rechtman LR, et al. Predicting surgical treatment outcomes of invasive breast cancers with breast-specific gamma imaging (BSGI). Chicago: RSNA, 2012: DOI: .
[5]
Koo HR, Moon WK, Cho N, et al. Relationship between quantitative FDG uptake on PET and immunohistochemical subtypes of breast cancers. Chicago: RSNA, 2012: DOI: .
[6]
Kiyoto S, Sugawara Y, Hosokawa K, et al. FDG PET/CT can predict pathological complete response and clinical outcome after neoadjuvant chemotherapy in breast cancer patients. Chicago: RSNA, 2012: DOI: .
[7]
Nakajima N, Kataoka, M, Sugawara Y, et al. Prognostic value of pre-treatment standardized uptake value (SUV) parameters in stage II-III breast cancer treated with postmastectomy radiotherapy (PMRT). Chicago: RSNA, 2012: DOI: .
[8]
Ahn HS, Yun BL, Kim SM, et al. Does adding optical diffusion imaging to us improve the differentiation between benign and malignant breast lesions? Observer performance study. Chicago: RSNA, 2012: DOI: .
[9]
Choi WJ, Kim HH, Kim H, et al. Optical diffusion breast imaging; correlation of parameters in optical imaging with maximum standardized uptake value in breast cancer patients. Chicago: RSNA, 2012: DOI: .
[10]
Sklair-Levy M, Mayer A, Sella T, et al. Non-invasively detection of vascular map asymmetry in breast cancer using novel functional infrared imaging. Chicago: RSNA, 2012: DOI: .
[11]
Pinker-Domenig K, Bickel H, Helbich TH, et al. BI-RADS®-based combination of CE-MRI and DWI obviates unnecessary breast biopsies. Chicago: RSNA, 2012: DOI: .
[12]
Yoo, H, Shin HJ, Cha JH, et al. The diagnostic value of apparent diffusion coefficient and quantitative kinetic analysis for predicting malignancy in patients with newly diagnosed breast cancer. Chicago: RSNA, 2012: DOI: .
[13]
Olson ML, Kurland B, Chai X. Detection and characterization of mammographically and clinically occult suspicious breast MRI lesions with diffusion weighted imaging at 3 T. Chicago: RSNA, 2012: DOI: .
[14]
Bickel H, Pinker-Domenig K, Bogner W, et al. Diffusion-weighted imaging: a noninvasive biomarker for breast cancer invasiveness. Chicago: RSNA, 2012: DOI: .
[15]
Pediconi F, Vasselli F, Roselli, A, et al. Breast MRI at 3 T: role of unenhanced MRI (DWI combined with T2 IDEAL sequence) vs CE-MRI in the assessment of response to neo-adjuvant chemotherapy. Chicago: RSNA, 2012: DOI: .
[16]
Schiani E, Cristel G, Losio C, et al. Diffusion-weighted magnetic resonance imaging in breast cancer: a promising tool to predict tumor aggressiveness. Chicago: RSNA, 2012: DOI: .
[17]
Benveniste AP, Dogan BE, Fox PS, et al. Is There a role for ADC values in predicting breast cancer prognostic factors? Chicago: RSNA, 2012: DOI: .
[18]
Cho G, Moccaldi M, Moy L, et al. Observation of time-dependent DTI Anisotropy in breast fibroglandular tissue. Chicago: RSNA, 2012: DOI: .
[19]
Penn AI, Rockvile, Hruska CB, et al. Discrimination of benign from malignant breast lesions on DTI using novel feature obtained from ADC on lesion and ADC gradient in peri-tumor. Chicago: RSNA, 2012: DOI: .
[20]
Au WF, Ghai S, Crystal P, et al. Quantitative shear wave elastography: performance in characterization of solid breast masses. Chicago: RSNA, 2012: DOI: .
[21]
Lee SH, Moon WK, Cho N, et al. Two-view vs single-view shear-wave elastography (SWE): a comparison of observer performance in differentiating benign from malignant solid breast masses. Chicago: RSNA, 2012: DOI: .
[22]
Lee SH, Chang JM, Moon WK, et al. Added value of shear-wave elastography (SWE) color scoring system and quantitative elasticity values in evaluation of ultrasound (US) detected breast masses. Chicago: RSNA, 2012: DOI: .
[23]
Gweon HM, Youk JH, Kim J, et al. Qualitative assessment in shear-wave elastography for breast masses: comparative analysis of E value and color overlay pattern classification. Chicago: RSNA, 2012: DOI: .
[24]
Kim MY, Cho N, Yi A, et al. Complex cystic breast masses: role of sonoelastography in distinguishing benign from malignant lesions and in the biopsy decision. Chicago: RSNA, 2012: DOI: .
[25]
Evans A, Whelehan P, Vinnicombe SJ, et al. What are the pathological characteristics of breast cancers misclassified as benign by ultrasound shear wave elastography? Chicago: RSNA, 2012: DOI: .
[26]
Chang JM, Lee, SH, Moon WK, et al. Stiffness values measured by shear-wave elastography correlated with aggressive breast cancer phenotype. Chicago: RSNA, 2012: DOI: .
[27]
No CJ, Sanders L, Chin JW, et al. The impact of breast cancer screening with MRI on patient adherence to annual mammography screening schedules in a high risk population in a community setting. Chicago: RSNA, 2012: DOI: .
[28]
Schrading S, Schild HH, Kuhl CK. MRI screening of women at average risk of breast cancer. Chicago: RSNA, 2012: DOI: .
[29]
Wooten K, Weinstock C, Stokum C, et al. Screening magnetic resonance imaging (MRI) as an adjunct to mammography (MG) in asymptomatic breast cancer survivors. Chicago: RSNA, 2012: DOI: .
[30]
Tsang Mui Chung M, Lourenco AP, Mainiero MB, et al. Screening breast mri in women with a personal history of breast cancer. Chicago: RSNA, 2012: DOI: .
[31]
Kaiser CG, Reich C, Wasser K, et al. Economic aspects of MR-mammography in dense breasts. Chicago: RSNA, 2012: DOI: .
[32]
Johnson KS, Soo MS, Holbrook AI, et al. Are screening MRI recall rates related to temperament or experience? Chicago: RSNA, 2012: DOI: .
[33]
Dontchos B, Demartini WB, Rahbar H, et al. Influence of menstrual cycle timing on screening breast MRI performance in pre-menopausal women. Chicago: RSNA, 2012: DOI: .
[34]
Miravete PM, Sainz M, Garcia-Lallana A, et al. The role of additional digital tomosynthesis combined with digital mammography. Chicago: RSNA, 2012: DOI: .
[35]
Rose SL, Ice MF, Nordmann AS, et al. A comparison of recall rates between full field digital mammography (FFDM) and full field digital mammography plus tomosynthesis in a community setting. Chicago: RSNA, 2012: DOI: .
[36]
Hass B, Kalra VB, Raghu M, et al. Performance of digital breast tomosynthesis compared to conventional digital mammography for breast cancer screening. Chicago: RSNA, 2012: DOI: .
[37]
Destounis SV, Murphy PF, Seifent PJ, et al. Experience with combination 2D/3D breast tomosynthesis vs FFDM in the screening environment. Chicago: RSNA, 2012: DOI: .
[38]
Kalra VB, Haas B, Butler RS, et al. Time for tomosynthesis: screening combined digital breast tomosynthesis vs. full-field digital mammography interpretation time in clinical practice: a prospective study of 300 cases. Chicago: RSNA, 2012: DOI: .
[39]
Garrett JW, Tang J, Burnside ES, et al. Dose reduction in digital breast tomosynthesis with prior image constrained compressed sensing (PICCS). Chicago: RSNA, 2012: DOI: .
[40]
Pinker-Domening K, Bickel H, Bogner W, et al. Assessment of response to neoadjuvant chemotherapy with high resolution MRI at 3 T: correlation with pathological response. Chicago: RSNA, 2012: DOI: .
[41]
Bickel H, Pinker-Domening K, Bogner W, et al. Assessment of response to neoadjuvant chemotherapy with diffusion weighted imaging at 3 T. Chicago: RSNA, 2012: DOI: .
[42]
Budreau D, Giger ML, Lan L, et al. Breast MRI-based feature analysis in predicting neoadjuvant therapy response. Chicago: RSNA, 2012: DOI: .
[43]
Arlinghaus LR, Abramson RG, Chakravathy AB, et al. DW-MRI for predicting the response of locally advanced breast cancer to neoadjuvant chemotherapy. Chicago: RSNA, 2012: DOI: .
[44]
Li X, Arlinghaus LR, Abramson RG, et al. Towards optimization of DCE-MRI analysis for predicting the response of breast cancer to neoadjuvant chemotherapy. Chicago: RSNA, 2012: DOI: .
[45]
Telesca M, Pediconi F, Luciani ML, et al. Accuracy of 3 T magnetic resonance imaging with a high-relaxivity contrast agent in assessing treatment response in patients with advanced breast cancer undergoing neoadjuvant chemotherapy. Chicago: RSNA, 2012: DOI: .
[46]
Davies BE, Kirchin MA, Bensel K, et al. Pharmacokinetics and safety of gadobenate dimeglumine (Multihance) in subjects with impaired liver function. Invest Radiol, 2002, 37(5): 299-308.
[47]
Ko ES, Han B, Shin JH, et al. Analysis of factors influencing accuracy of MRI for predicting response after neoadjuvant chemotherapy in locally advanced breast cancer. Chicago: RSNA, 2012: DOI: .
[48]
Drisis S, Stathopoulos K, Capelan M, et al. The impact of breast cancer subtypes on DCE-MRI as a surrogate marker for locally advanced breast cancer. Chicago: RSNA, 2012: DOI: .
[49]
Ananyhasivan R, Parameshwaran R, Nagaraj C, et al. Radio-guided occult lesion localization (ROLL) for non-palpable breast lesions: the indian experience. Chicago: RSNA, 2012: DOI: .
[50]
King V, Sung JS, Thornton C, et al. Safety and efficacy of radioactive seed localization with I-125 prior to lumpectomy and/or excisional biopsy. Chicago: RSNA, 2012: DOI: .

PREV Current status of MR colonography
NEXT The progress of head and neck radiology on Radiological Society of North America 2012
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn